CHARLOTTESVILLE, Va., Jan. 5, 2012 /PRNewswire/ -- ZyGEM Corp. Ltd., a developer and marketer of innovative products for the analysis of DNA and other nucleic acids, and the US Army Medical Research Institute of Infectious Diseases (USAMRIID), today announced the signing of a Cooperative Research and Development Agreement (CRADA) for the development of simplified sample processing solutions for biothreat agents. The two organizations will collaborate on the development, testing and validation of new solutions for the rapid and efficient extraction of DNA and other nucleic acids for the detection of biothreat agents and other pathogens from a variety of sample matrices, including buffer, serum, whole blood and swabs.
The CRADA effort will leverage ZyGEM's proprietary technology for the extraction of DNA and other nucleic acids from diverse samples using thermophilic enzymes produced by extremophile organisms. USAMRIID and ZyGEM intend to collaboratively explore the utility of a number of enzymes capable of isolating nucleic acids. ZyGEM's enzyme technologies will be evaluated and optimized to provide sample processing capabilities for the detection of a variety of biothreat agents and for use in challenging environments.
ZyGEM currently markets products based on a similar approach. The unique properties of its EA1 protease, the key ingredient in the company's prepGEM™, forensicGEM™, livestockGEM™ and RNAGEM™ families of nucleic acid extraction kits, make possible cost effective and flexible solutions for researchers performing a wide variety of studies, including human genotyping, animal testing and basic research. This enzyme has characteristics that make it well-suited for DNA and RNA extraction in a closed tube, where a simple temperature shift modulating enzyme activity rapidly provides high quality DNA and RNA that is ready for analysis by most PCR-base
|SOURCE ZyGEM Corp. Ltd.|
Copyright©2010 PR Newswire.
All rights reserved